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Prostate cancer is currently the sixth most common cancer in
Singapore (Chia et al, 1996). It has however been showing an
average annual increase in incidence of some 4.6% over the last 25
years (Chia et al, 1996) and coupled with an ageing population
(Goh, 1997), prostate cancer is expected to become a significant
source of cancer-related mortality in Singapore. Prostate cancer is a
heterogeneous disease, and as such presents significant problems in
prognostication, despite a range of clinical and pathological markers
of tumour aggressiveness. As such, attention has focused on under-
standing the underlying genetic events in attempts to determine
appropriate clinicopathologic markers of tumour behaviour, as well
as to aid in the development of novel treatment strategies.
The most commonly altered gene in a wide variety of tumours is
the p53 tumour suppressor gene (Greenblatt et al, 1994) and in
western population considerable data has shown that lesions of the
p53 tumour suppressor gene are significantly associated with
prostate cancer disease progression and a poorer patient prognosis,
both with respect to overexpression of the protein (Thomas et al,
1993; Bauer et al, 1995; 1996; Shurbaji et al, 1995; Kuczyk et al,
1998) and mutation of the gene (Effert et al, 1992; Eastham et al,
1995; Stapleton et al, 1997). However, data on Japanese patients
(Uchida et al, 1993; Watanabe et al, 1994) has shown that p53
overexpression and mutation occur in prostate tumour with a
considerably lower frequency than is found in Western or
Caucasian populations.
However, the p53 tumour suppressor gene is implicated in a
wide range of cellular activities including DNA replication and
regulation of the cell cycle. In particular the p53 tumour
suppressor gene is involved in regulating some apoptotic pathways
(Deppert, 1994) and it is possible that lesions elsewhere in the
regulation of apoptosis are a predominant factor in prostate
tumorigenesis in Asian populations. The p53 tumour suppressor
gene is believed to control apoptosis by regulating the expression
of the apoptosis associated genes bcl-2 and bax (Miyashita et al,
1994; Miyashita and Reed, 1995) and it is possible that alterations
in the expression of one of these genes may result in a tumorigenic
pathway the equivalent of a lesion in the p53 gene that is found in
Western populations.
In addition to data showing discordant rates of p53 involvement
in prostate tumours from Western and Japanese cohorts, further
studies have also indicated sharply discordant rates of ras muta-
tion. In particular studies on Japanese patients have shown rates of
ras mutation of up to 25% (Anwar et al, 1992; Shiraishi et al,
1998), while studies on Caucasian patients note that this gene is
rarely if ever mutated (Gumerlock et al, 1991; Moul et al, 1992).
In the absence of data on prostate tumorigenesis in population
cohorts other than Caucasian or Japanese, we therefore undertook
to examine archival specimens of prostate tumours from
Singapore for a range of markers, including the expression of p53,
bax and bcl-2, and the mutation of the ras family of genes. At the
same time we also examined the samples directly for the presence
of apoptotic cells using the terminal deoxynucleotide transferase
(TdT)-mediated nick end labelling or TUNEL methodology
(Gavrieli et al, 1992).
MATERIALS AND METHODS
Patients and samples
Samples used in this study were prostatic archival paraffin blocks
obtained after transurethral resection of the prostate (TURP) from
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doi: 10.1054/ bjoc.2000.1355, available online at http://www.idealibrary.com on patients admitted to the Department of General Surgery, Tan Tock
Seng Hospital between 1993 and 1998. No initial chemotherapy,
radiotherapy or hormonal therapy was given before tumour exci-
sion. All samples were included only after histopathological diag-
nosis and tumours were graded according to the Gleason system
(Gleason, 1977). All patients were classified according to ethnic
group as given on their National Registration Identity Certificates,
and comprised 50 Chinese, eight Malay and four Indian males.
Mean age of patients was 75.19 ± 8.59 (range 45–91) years. All
original haematoxylin and eosin slides were reviewed prior to
selection of blocks containing the largest tumour volume. Slides
were graded for gene expression by a single pathologist. At the
end of the study period 29 (47%) patients had died of their disease.
Mean follow-up was 28.66 ± 20.12 (range 1–77) months.
Information on patient survival was obtained from the Singapore
Cancer Registry and hospital clinical records. Patients that had
died of causes other than their disease were censored from the
survival analysis at the time of death. Lymph-node status and the
presence of distant metastatic lesion were determined by CT
pelvic scan and bone scan respectively. Fifty-eight percent of
patients (36/62) underwent bilateral subcapsular orchidectomy.
Fourteen of the patients in this cohort refused further investigation
or treatment after surgery.
Immunohistochemistry
Immunoreactive p53, bcl-2 and bax were detected by the labeled
streptavidin–biotin method (Hsu et al, 1981). Several contiguous
10 µ M sections were mounted on poly-L-Lysine treated slides,
dewaxed in xylene and rehydrated in successive immersion in
absolute ethanol, 70% ethanol and distilled water. One section was
stained with haematoxylin and eosin. The remaining sections were
extensively rinsed in phosphate buffered saline (PBS) and endoge-
nous peroxidases were quenched in 3% hydrogen peroxide for 
5 min. After washing in PBS slides were then incubated with
blocking reagent for 20 min (Dako LSAB Kit, Dako Carpinteria,
CA, USA). Incubation with primary antibody followed rinsing
three times with PBS. Incubation was undertaken at 4° C overnight
with either a 1:50 dilution of anti-p53 monoclonal antibody DO-7
(Dako), a 1:100 dilution of anti-bcl-2 polyclonal antibody Ab-2
(Oncogene Research Products, Cambridge, MA, USA) or a 
1:100 dilution of anti-bax polyclonal antibody Ab-1 (Oncogene
Research Products). Following three rinses with PBS, slides were
then incubated with linking antibody (Dako) for 10 min, followed
by 10 min with streptavidin–horseradish–peroxidase diluted as
recommended by the manufacturer and then incubated for 8 min
with the chromogen 3,3′ -diaminobenzidine tetrahydrochloride
(DAB; Dako). After each incubation samples were rinsed three
times with PBS. Samples were counterstained with haemotoxylin
for 1 min and nuclei blued in water. Slides were then dehydrated
and mounted. Specificity of antibody binding was confirmed by
undertaking, in parallel appropriate negative (no antibody) and
positive controls. Positive controls included a fresh, flash-frozen
colorectal adenocarcinoma previously characterized as strongly
over-expressing p53 (Smith et al, 1996), as well as fresh, flash-
frozen colorectal mucosae for bax and bcl-2. Pattern of expression
for bax and bcl-2 control specimens conformed to established
profiles of expression for these genes (Ogura et al, 1999). Analysis
was undertaken in duplicate on successive occasions. All speci-
mens were examined across the whole section by light
microscopy, and were deemed positive if there was evidence of
focal positivity or greater.
TUNEL analysis
TUNEL analysis (Gavrieli et al, 1992) was undertaken with the
Cell Death Kit (Boehringer Mannheim GmbH, Penzburg,
Germany) essentially as recommended by the manufacturer.
Briefly, samples were dewaxed in two changes of xylene followed
by sequential rehydration in two changes of ethanol (absolute and
70%) followed by distilled water. Tissue sections were incubated
with 25 µ g ml–1 Proteinase K in 10 mM Tris-HCl, pH 7.4 for 
15 min at room temperature. Following rinsing in PBS, exogenous
peroxidases were quenched in 3% hydrogen peroxide for 5 min.
After rinsing in PBS, slides were incubated in blocking solution
for 30 min at room temperature. Slides were incubated with 100 µ l
of the TUNEL reaction mixture for 60 min at room temperature in
a humidified atmosphere. Following rinsing in PBS slides were
incubated with 100 µ l converter-peroxidase solution, pre-diluted
1:5 in blocking solution and incubated for a further 30 min at room
temperature. After rinsing in PBS samples were incubated with 
1 mg ml–1 DAB substrate and incubated for 8 min at room temper-
ature. Slides were subsequently washed, counterstained with
haemotoxylin and mounted. Specificity of TUNEL reactivity was
confirmed by undertaking in parallel appropriate negative (no
antibody) and positive (fresh, flash-frozen colorectal mucosae)
controls. Pattern of TUNEL expression was as reported by others
(Moss et al, 1996).
Ras analysis
Genomic DNA was prepared from one 10 µ m thick section of
paraffin-embedded tissue from each tumour. Tissue section was
placed in a 1.5 ml centrifuge tube together with 1 ml of xylene and
incubated on a tube rotator for 30 min at room temperature and
contents pelleted by centrifugation. Two further resuspension in
xylene and pelleting steps were undertaken. The pellet was washed
twice with absolute ethanol and air-dried. Pellet was resuspended
in 100 µ l H2O containing 20 µ g Proteinase K (Boehringer
Mannheim) and 5% SDS and incubated for 3 days at 50° C.
Proteinase K was inactivated by heating to 90° C and debris
pelleted by centrifugation. The supernatant was extracted twice
with an equal volume of phenol and once with chloroform. DNA
was precipitated by adding 2.5 volumes ice-cold ethanol and
sodium acetate to 0.3 molar and incubating at –80° C for 15 min
followed by pelleting by centrifugation. DNA was resuspended in
sterile distilled water.
c-Ki-ras
A 176 bp fragment of exon 1 of the c-Ki-ras gene was amplified
from all DNA samples using custom synthesized oligonucleotides:
5′ -CATGTTCTAATATAGTCACA-3′ (forward); and 5′ -AACAA-
GATTTACCTCTATTG-3′ (reverse) essentially as described previ-
ously (Elnatan, 1996a; 1996b).
H-ras
A 145 bp fragment of exon 1 of the H-ras gene was amplified
from all DNA samples using the custom synthesized oligo-
nucleotides: 5′ -GGCAGGAGACCCTGTAGGAG-3′ (forward); and
5′ -GTATTCGTCCACAAAATGGTTCT-3′ (reverse): Following an
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40 cycles of 94° C for 1 min (denature), 50° C for 2 min (anneal)
and 72° C for 3 min (extend).
N-ras
A 109 bp fragment of exon 1 of the N-ras gene was amplified 
from all samples using the custom synthesized oligonucleotides:
5′ -GACTGAGTACAAACTGGTGG-3′ (forward); and 5′ -CTC-
TATGGTGGGATCATATT-3′ (reverse). Following an initial dena-
turation at 94° C, samples were subjected to 40 cycles of 94° C for
1 min (denature), 50° C for 2 min (anneal) and 72° C for 3 min
(extend).
Single-stranded conformational polymorphisms (SSCP)
All ras PCR products were analysed by single-stranded conforma-
tional polymorphism analysis (Orita et al, 1989). Briefly, ras PCR
products were denatured at 95° C and loaded onto a 15% (K-ras
and N-ras) or 28% (N-ras) 29:1 acrylamide:bisacrylamide poly-
acrylamide gel containing 5% glycerol Mighty Small™ (Hoefer,
Amersham Pharmacia Biotech, Uppsala, Sweden). Samples were
electrophoresed at 200 volts for 3.5 h. After electrophoresis, DNA
bands were developed by silver staining using the Hoefer
Automated Gel Stainer (Hoefer, Amersham Pharmacia Biotech)
and the protocol of Soong and Iacopetta (1997).
p53 mutation analysis
Samples positive for p53 overexpression were subjected to exon-
specific PCR for exons 4–9 of the p53 gene followed by SSCP
analysis essentially as described above. Aberrantly migrating
bands were excised from the gel matrix after silver staining using
the protocol of Soong and Iacopetta (1997), and re-amplified using
the same exon-specific primers. The amplification products were
then purified by agarose gel electrophoresis and excised from the
gel matrix, after which templates were purified using the Qiaex
PCR Purification Kit (Qiagen, Hilden, Germany). DNA
sequencing reactions were performed using the Big Dye
Termination reaction kit (PE Applied Biosystems, Foster City, CA,
USA) on approximately 60–90 ng of template from above.
Analysis was undertaken on an automated ABI 377-18 DNA
Sequencer (PE Applied Biosystems).
Statistical analysis
Two by two tables were analysed by the χ 2 test. Univariate survival
analysis was carried out using the method of Kaplan–Meier and
differences between survival curves were compared using the log-
rank test. All tests were two-tailed and statistical significance was
assumed when P < 0.05. Analyses were carried out using the SPSS
software package (Chicago, IL, USA).
RESULTS
Sixty-two formalin fixed, paraffin embedded specimens of prostatic
cancer from Singaporean patients were analysed for the pattern of
expression of p53, bcl-2 and bax, as well as for the presence of apop-
totic cells using the TUNEL methodology (Table 1). At the same
time samples were also examined for possible mutation of K-ras, H-
ras and N-ras. For all samples one 5 µ m section was stained with
haematoxylin and eosin to confirm identity of the sample and to
identify areas of necrosis prior to further analysis.
p53 overexpression and mutation
Overexpression of the p53 protein using monoclonal antibody DO-
7 was detected in tumours from two patients (3%). In both cases
staining was nuclear (Figure 1). To determine if overexpression was
the result of a point mutation of the p53 gene, we extracted DNA
from further sections of these two samples and undertook exon-
specific PCR for exons 4–9 of the p53 gene, and products were
analysed by SSCP (Orita et al, 1989). Aberrantly migrating bands
were observed for exon 7 for both samples after silver staining of
the gel. The aberrant bands were excised from the gel and subjected
to re-amplification with exon 7-specific primers. Products were
analysed by DNA sequencing and analysis on an ABI automated
sequencer. DNA sequence analysis (Figure 1) determined that the
lesions in these samples were a G to C transversion resulting in the
substitution of a glycine with an alanine at codon 245 for one
patient and a G to A transition resulting in the substitution of an
Arginine with a Histidine at codon 237 for the second patient.
Analysis of ras genes
Genomic DNA was prepared from one 10 µ m section from all
samples. This was used as a template to amplify portions of the K-
ras, N-ras and H-ras exon 1. These samples were screened by
Single Stranded Conformational Polymorphisms (Figure 2), a
technique we have previously shown to be sensitive to the pres-
ence of ras mutations in colorectal adenocarcinomas (Eluatan,
1996a; 1996b). Of the 186 PCR products analysed, a single sample
with aberrantly migrating bands was detected. This was in the H-
ras gene of one patient. The aberrantly migrating bands were
excised from the gel matrix after silver-staining, re-amplified with
H-ras exon 1-specific primers and analysed by DNA sequencing
and analysis on an Automated ABI 377 DNA Sequencer. The
mutation was determined to be a G to T transversion at position
–10 with respect to the A of the translation start site ATG.
Bax and bcl-2 expression
Analysis of bax protein expression was undertaken with a mono-
clonal antibody directed against human bax (Ab-1). Evidence of
bax protein expression was detected in the neoplastic cells in 76%
(47/62) of samples (Figure 3, Table 1). Consistent with the known
location of the bax protein (Wolter et al, 1997), staining was
cellular. Bax staining was heterogeneous with some samples
showing extensive staining across the entire section, while others
showed a relatively restricted distribution to one or a few regions
of the sample. In eight cases normal and/or hyperplastic cells were
also present in the section, all of which were positive for bax
expression. In five of these cases the neoplastic cells were also
positive for bax expression, while in three cases normal/hyper-
plastic tissues were positive while the tumour mass was negative
for bax expression. No case of bcl-2 immunostaining was
observed (Figure 3), although staining was appropriately noted in
positive control samples (data not shown). Bcl-2 immunoreactivity
was also not noted in either normal or hyperplastic tissues.
Univariate survival analysis was undertaken with patients strati-
fied according to bax expression status. Patients who expressed
Asian prostate tumours 763
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Table 1 Summary of results from 62 patients
Sample Age Gleason Lymph Stage Distant POTd p53 bax TUNEL Follow-up Status
/Racea score nodeb metastasesc
1/C 73 4+5 Y D2 Y Y N N N 10 Dead
2/C 78 4+4 Y C1 N Y N N N 77 Alive
3/C 74 5+4 Y D2 Y Y N N N 25 Dead
4/C 81 4+5 N B N Y N Y N 27 Dead
5/C 61 5+2 Y D2 Y Y N Y Y 14 Dead
6/C 87 2+1 N A2 ND N N Y N 10 Dead
7/C 75 3+2 N ND ND Y N N N 72 Alive
8/C 80 3+1 Y D N Y N Y N 23 Dead
9/C 75 4+3 ND ND ND ND N Y Y 5 Dead
10/C 63 4+3 Y D3 Y Y N Y Y 34 Dead
11/C 68 4+3 Y D3 Y Y N Y Y 28 Dead
12/C 75 3+2 N C1 ND N N Y N 23 Dead
13/C 70 2+3 N B ND N N Y Y 24 Dad
14/C 76 3+4 N B N Y N N N 69 Alive
15/C 79 2+3 ND ND ND ND N N N 66 Alive
16/C 67 5+5 ND ND ND Y N N N 2 Alive
17/C 75 5+3 Y D3 Y Y N Y Y 1 Dead
18/C 77 4+4 ND ND ND ND N Y Y 8 Dead
19/C 78 5+4 Y D3 Y N N Y N 1 Dead
20/C 90 2+3 Y D3 Y Y N Y Y 13 Dead
21/C 63 3+3 N A1 N N N N N 58 Alive
22/C 83 3+4 Y D2 Y Y N Y Y 49 Dead
23/C 65 3+5 Y D1 N Y N Y Y 5 Dead
24/C 71 3+4 Y D2 Y Y N Y Y 55 Alive
25/C 63 4+3 Y D2 Y Y N Y Y 30 Alive
26/C 81 5+2 N D2 Y Y Y Y N 24 Alive
27/C 81 4+5 Y D2 Y Y N Y Y 12 Dead
28/C 84 4+3 Y D2 Y Y N Y Y 23 Alive
29/C 69 3+2 N C1 N N N Y Y 22 Alive
30/C 84 3+4 N B N Y N Y N 21 Alive
31/C 89 4+3 Y D2 Y Y N Y Y 5 Dead
32/C 64 4+5 Y D1 N Y N Y N 53 Alive
33/C 69 3+4 N A2 N Y N N Y 52 Alive
34/C 88 5+4 ND ND ND ND N Y N 20 Dead
35/C 79 3+4 ND D1 ND N N Y Y 47 Alive
36/C 82 4+5 ND ND ND ND N Y Y 1 Dead
37/C 78 4+3 N A2 N Y N Y N 14 Dead
38/C 74 1+2 N A2 N Y N N Y 43 Alive
39/C 69 3+4 N D2 Y Y N Y Y 43 Alive
40/C 68 5+5 N A1 N Y N N Y 39 Alive
41/C 81 4+3 Y D2 Y Y N Y Y 37 Alive
42/C 91 3+5 Y D2 Y Y N Y Y 33 Alive
43/C 86 3+4 N A2 N N N Y Y 32 Alive
44/C 78 4+5 N A2 N Y N Y Y 13 Dead
45/C 79 4+5 Y D2 Y Y N Y Y 30 Alive
46/C 68 4+5 Y D2 Y Y N Y Y 29 Alive
47/C 83 4+5 N D2 Y Y N Y Y 28 Alive
48/C 76 4+3 Y D3 Y Y N Y Y 28 Alive
49/C 78 4+5 N A1 N Y N N N 27 Alive
50/C 64 3+4 N D2 Y Y N Y Y 25 Alive
51/M 72 4+2 Y D2 Y Y N N N 77 Alive
52/M 82 5+4 N C1 N Y N Y Y 15 Dead
53/M 45 4+4 ND D ND ND N Y N 16 Dead
54/M 79 4+3 Y C1 ND Y N N Y 65 Alive
55/M 67 4+5 Y D2 Y N N Y Y 13 Dead
56/M 87 4+4 Y D1 Y Y N Y Y 51 Alive
57/M 79 5+4 N A2 N Y N Y Y 4 Dead
58/M 66 4+5 N D2 Y Y N Y N 13 Dead
59/I 80 2+3 N A2 N N N N N 27 Alive
60/I 66 3+4 Y D1 N Y Y Y Y 33 Alive
61/I 69 3+4 ND A1 ND Y N Y Y 10 Dead
62/I 80 4+3 N A2 N Y N Y N 23 Alive
aRace: C = Chinese, M = Malay, I = Indian; bLymph node status: Y = involved, N = not involved; cDistant metastases: Y = distant metastasis, N = no distant
metastasis; dPOT (administration of post-operative therapy): Y = yes, N = noAsian prostate tumours 765
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Figure 1 Immunohistochemical and sequence analysis of a prostatic
tumour specimen. (Top) Section of an archival prostatic tumour from an
(Indian) Singaporean after staining with monoclonal antibody DO7
(magnification × 200). (Bottom) Partial DNA sequence of exon 7 of the p53
gene from the same patient as above after analysis on an Automated ABI
DNA Sequencer. The mutation (G to A) is indicated (*)
H-ras
N-ras
K-ras
Figure 2 Single stranded conformational polymorphism analysis of exon 1
of the H-ras, N-ras and K-ras genes of nine prostatic tumours. PCR samples
are denatured and run on appropriate polyacrylamide gels. After
electrophoresis samples are detected by silver-staining
AB
D C
Figure 3 Immunohistochemical analysis of prostate carcinoma specimens. Formalin-fixed, paraffin-embedded prostatic carcinoma sections positive (A) 
and negative (B) for apoptotic cells (TUNEL analysis) and positive for bax (C) and negative for bcl-2 (D). A, C and D are from one patient. Original 
magnification × 100bax were shown to have a significantly poorer long-term survival
than those patients who did not express bax, both in the whole
patient cohort (P < 0.005) and in a sub-cohort of 50 patients of
Chinese origin (P = 0.02, Figure 4). Fourteen of the patients in this
cohort refused further investigation or treatment, and hence
information on lymph-node status and metastatic lesions is only
available for 48 of the patients. We attempted to undertake a
multivariate analysis using this smaller cohort. However, none of
the terms were entered into the model, although bax expression
remained the variable with the highest level of significance 
(P = 0.0535).
TUNEL analysis
Terminal deoxynucleotide transferase (TdT)-mediated nick end
labeling staining was undertaken on all samples, and 61% (38/62)
of samples evinced some positively staining cells, although only
46% showed evidence of heavy and/or extensive staining (Figure
3). The presence of apoptotic cells was positively associated with
the presence of bax expression in both the whole patient cohort 
(P = 0.002, Fisher’s Exact Test, Table 2), as well as in a sub-cohort
of 50 patients of Chinese origin (P = 0.005, Fisher’s Exact Test,
Table 2). Univariate survival analysis noted no association
between survival and the presence or absence of apoptotic cells, in
either the whole cohort (P = 0.8) or the sub-cohort of Chinese
patients (P = 0.9).
DISCUSSION
In Western population cohorts activation of any member of the ras
gene family is rare (Gumerlock et al, 1999; Moul et al, 1992), and
it is believed that ras activation does not play a significant role in
prostate tumorigenesis. In contrast, Anwar and colleagues (1992)
have reported a rate of 24% of prostatic carcinomas from Japanese
patients showing mutation of either H-ras (predominantly), N-ras
or K-ras. While some studies on prostatic carcinomas from
Japanese patients have reported somewhat lower rates of ras acti-
vation (Konishi et al, 1997), it is clear that unlike prostate cancers
from Western cohorts, activation of ras genes is a significant event
in prostate tumorigenesis in Japanese patients. The patients exam-
ined here are the first non-Caucasian, non-Japanese patients to be
examined for ras mutation, and no case of ras mutation was
observed. This is unlikely to be due to technical or sensitivity
problems as we have previously extensively analysed ras muta-
tions in colorectal adenocarcinomas (Elnatan, 1996a; 1996b), and
here detected one base alteration in a prostate carcinoma from a
Singaporean Indian patient. The position of the alteration, within
the 5′ -untranslated region makes it unlikely to have functional
significance, and may indeed represent a polymorphic variant. The
lack of somatic material makes it impossible to distinguish this
change as tumour-specific. These results suggest that like prostate
cancers from Western cohorts, ras mutation in non-Japanese Asian
prostate cancers is unlikely to play a biologically significant role.
In cohorts from Western countries such as the USA, lesions of
the p53 gene (such as overexpression of the protein or mutation 
of the gene) are found in up to 65% of prostate tumours
(Theodorescu et al, 1997) and such lesions have been shown to be
significantly associated with both tumour progression and a poorer
patient prognosis (Effert et al, 1992; Thomas et al, 1993; Bauer et
al, 1995; 1996; Eastham et al, 1995; Shurbaji et al, 1995; Stapleton
et al, 1997; Kuczyk et al, 1998). In these cohorts, bcl-2 expression
is elevated (Bauer et al, 1995) and bcl-2 expression has been found
to be associated with tumour progression (Furuya et al, 1996;
Krajewska et al, 1996; Johnson et al, 1998) and a poorer patient
prognosis (Bauer et al, 1995). It would seem that in these patients,
p53 mutation results in a release of the suppression of bcl-2,
leading to loss of appropriate apoptosis, as well as an insensitivity
to apoptotic stimuli (Huang et al, 1998; Johnson et al, 1998). The
finding that bax is expressed in all prostate tumours (Krajewska et
al, 1996; Johnson et al, 1998) would indicate that the mutated p53
retains the ability to activate the transcription of bax, a finding that
is consistent with data that shows that the different functions of
p53 (apoptosis and transcription) can be differently inactivated by
non-sense mutations (Bissonette et al, 1997; Guillouf et al, 1998).
In Asian cohorts however, the involvement of p53 (overexpres-
sion and/or mutation of the gene) is significantly lower, ranging
from 3% in this study to approximately 10% in studies from Japan
(Uchida et al, 1993; Watanabe et al, 1994), and both p53 and bcl-2
overexpression have been shown not to have prognostic informa-
tion in a cohort of Japanese patients (Masuda et al, 1998). In our
cohort of patients we find no evidence of bcl-2 expression in the
tumour mass. This result would be consistent with the low rate of
p53 inactivation found in these tumours, with wild-type p53 being
able to appropriately suppress bcl-2 expression.
While bax expression has been noted in all tumour samples
from Caucasian cohorts (Krajewska et al, 1996; Johnson et al,
1998), we note bax expression in only some 76% of samples.
Where bax is expressed, we note, as would be expected, a signifi-
cant relationship with the presence of apoptotic cells. These results
would tend to suggest that, in Asian cohorts, the apoptotic
766 S-J Chia et al
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Figure 4 Survival analysis for 50 Chinese prostate tumour patients
stratified according to bax protein expression status. Black line: no bax
expression observed; red line: bax expression observed. The two curves are
significantly different (P < 0.02, log rank analysis)
Table 2 Association of bax expression with presence of TUNEL positive
cells. Figures in brackets are for Chinese patients only
TUNEL Negative TUNEL Positive
Bax Negative 11 (9) 4 (3)
Bax Positive 13 (10) 34 (28)pathway, at least with respect to p53, bax and bcl-2, is relatively
intact in the majority of tumours. Some 22% of tumours show no
evidence of bax expression, and only 26% of these tumours show
evidence of apoptotic cells. In these tumours therefore, the reduc-
tion in bax expression would perhaps be functionally equivalent to
an increase in bcl-2 seen in Caucasian populations (Bauer et al,
1995; Furuya et al, 1996; Krajewska et al, 1996; Johnson et al,
1998).
However, perhaps most surprising is the association between the
expression of bax and a poorer patient prognosis, a result found
both in the whole cohort, and in the subcohort of Chinese patients.
This result would suggest that the expression of bax is associated
with a more aggressive disease, and as such it is possible that these
tumours have cell populations that are turning over very rapidly,
and therefore have a greater probability of acquiring additional
genetic changes necessary for a more malignant phenotype. While
in some tumours, particularly those with a high proportion of
microsatellite instability (Thibodeau et al, 1993) such as hereditary
non-polyposis coli (Yagi et al, 1998) and gastric cancer (Oliveira
et al, 1998), the bax gene itself is a target of somatic mutation, in
these prostate tumours that is unlikely as there is a strong relation-
ship between bax expression and the presence of TUNEL positive
cells, suggesting that the bax protein is functionally active.
The summation of results here, for p53, ras, bcl-2 and bax
describe a prostate tumour that is genetically distinct from those
tumours from either Caucasian or Japanese cohorts, which in turn
are genetically distinct from each other. As such, prostate tumori-
genesis may represent the clearest example of genetic background
or ethnicity determining the pathway to tumorigenesis.
In the future, treatment options for prostate cancer are likely to
draw significantly upon our understanding of prostate tumour
biology and are likely to target specific genetic lesions (Bower and
Waxman, 1997). Given that evidence to date suggests that Asian
and Caucasian populations do not show similar routes to prostate
tumorigenesis, this will have profound effects on the viability of
novel anti-tumorigenic treatment regimes in Asian patients.
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